Calcium cycling in heart failure: How the fast became too furious

Cardiovascular Research

Volumn 62, Issue 3, 2004, Pages 439-441

  Armand, Anne Sophie ^a   De Windt, Leon J ^a  

^a HUBRECHT INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CHANNEL L TYPE;

AORTA STENOSIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; CARDIOMYOPATHY; EDITORIAL; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART TRANSPLANTATION; HEART VENTRICLE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SURGICAL PATIENT;

ANIMALS; CALCIUM; CALCIUM CHANNELS; CALCIUM-BINDING PROTEINS; CALCIUM-TRANSPORTING ATPASES; HEART FAILURE, CONGESTIVE; HUMANS; MICE; MICE, KNOCKOUT; MYOCARDIUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 2442557792     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.03.022     Document Type: Editorial

References (13)

1. Luo W., Grupp I.L., Harrer J., et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ. Res. 75(3):1994;401-409
2. Minamisawa S., Hoshijima M., Chu G., et al. Chronic phospholamban- sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 99(3):1999;313-322
3. Sato Y., Kiriazis H., Yatani A., et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J. Biol. Chem. 276(12):2001;9392-9399
4. del Monte F., Harding S.E., Dec G.W., Gwathmey J.K., Hajjar R.J. Targeting phospholamban by gene transfer in human heart failure. Circulation. 105(8):2002;904-907
5. Hoshijima M., Ikeda Y., Iwanaga Y., et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8(8):2002;864-871
6. Delling U., Sussman M.A., Molkentin J.D. Re-evaluating sarcoplasmic reticulum function in heart failure. Nat. Med. 6(9):2000;942-943
7. Song Q., Schmidt A.G., Hahn H.S., et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J. Clin. Invest. 111(6):2003;859-867
8. Freeman K., Lerman I., Kranias E.G., et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J. Clin. Invest. 107(8):2001;967-974
9. Kiriazis H., Sato Y., Kadambi V.J., et al. Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis. Cardiovasc. Res. 53(2):2002;372-381
10. Haghighi K., Kolokathis F., Pater L., et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111(6):2003;869-876
11. Janczewski A.M., Zahid M., Lemster B.H., et al. Phosholamban gene ablation improves calcium transients but not cardiac function in a heart failure model. Cardiovasc. Res. 62:2004;468-480
12. Wehrens X.H., Marks A.R. Altered function and regulation of cardiac ryanodine receptors in cardiac disease. Trends Biochem. Sci. 28(12):2003;671-678
13. Braz J.C., Gregory K., Pathak A., et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10(3):2004;248-254